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Abstract
Background: PET/MRI can be used for the detection of disease in biochemical recurrence (BCR) patients imaged
with 68Ga-PSMA-11 PET. This study was designed to determine the optimal MRI sequences to localize positive
findings on 68Ga-PSMA-11 PET of patients with BCR after definitive therapy. Fifty-five consecutive prostate cancer
patients with BCR imaged with 68Ga-PSMA-11 3.0T PET/MRI were retrospectively analyzed. Mean PSA was 7.9 ± 12.
9 ng/ml, and mean PSA doubling time was 7.1 ± 6.6 months. Detection rates of anatomic correlates for prostate-
specific membrane antigen (PSMA)-positive foci were evaluated on small field of view (FOV) T2, T1 post-contrast,
and diffusion-weighted images. For prostate bed recurrences, the detection rate of dynamic contrast-enhanced
(DCE) imaging for PSMA-positive foci was evaluated. Finally, the detection sensitivity for PSMA-avid foci on 3-
and 8-min PET acquisitions was compared.
Results: PSMA-positive foci were detected in 89.1% (49/55) of patients evaluated. Small FOV T2 performed
best for lymph nodes and detected correlates for all PSMA-avid lymph nodes. DCE imaging performed the
best for suspected prostate bed recurrence, detecting correlates for 87.5% (14/16) of PSMA-positive prostate
bed foci. The 8-min PET acquisition performed better than the 3-min acquisition for lymph nodes smaller
than 1 cm, detecting 100% (57/57) of lymph nodes less than 1 cm, compared to 78.9% (45/57) for the
3-min acquisition.
Conclusion: PSMA PET/MRI performed well for the detection of sites of suspected recurrent disease in patients with
BCR. Of the MRI sequences obtained for localization, small FOV T2 images detected the greatest proportion of PSMA-
positive abdominopelvic lymph nodes and DCE imaging detected the greatest proportion of PSMA-positive prostate
bed foci. The 8-min PET acquisition was superior to the 3 min acquisition for detection of small lymph nodes.
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Background
After initial definitive treatment of prostate cancer with
radical prostatectomy, brachytherapy, or external beam
radiation, prostate-specific antigen (PSA) may rise due
to local, regional, or systemic recurrence prior to the de-
velopment of clinical symptoms. This rise in pre-clinical
PSA is termed biochemical recurrence (BCR). After
prostatectomy, BCR is defined by the American
Urological Association as a PSA value of 0.2 ng/mL or
higher on two separate tests [1]. In patients treated with
radiation therapy, including external beam radiation and
brachytherapy, the RTOG-ASTRO Phoenix Consensus
Conference defined BCR as a rise in PSA by 2.0 ng/mL
above the PSA nadir [2]. Patients with BCR may be
assessed with a combination of technetium-99m bone
scintigraphy and periodic CT scans [3]. However, CT
scans do not accurately evaluate lymph nodes, especially
those smaller than 5 mm [4], and bone scintigraphy has
limited sensitivity and specificity for the detection of
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osseous metastases, due to radiotracer uptake by non-
metastatic lesions, most commonly degenerative diseases.
Prostate-specific membrane antigen (PSMA) is a
membrane protein that is overexpressed in prostate can-
cer cells in comparison to benign prostate cells and in-
creases in advanced stage and androgen-independent
prostate cancer [5]. Molecular imaging targeted to
PSMA has been shown to have a high detection rate of
lesions suspicious for local recurrence and metastatic
disease [6, 7]. In two intra-patient comparisons, for ex-
ample, 68Ga-PSMA-11 PET had a higher sensitivity than
fluorocholine PET, particularly in patients with a PSA
less than 2.0 ng/mL [6, 8].
While PSMA PET is highly sensitive for suspected
sites of prostate cancer recurrence, it does not provide
precise localization of the PSMA-avid foci. Therefore,
PET images need to be co-registered with images from
an additional modality for localization, and this has typ-
ically been done with CT scans because of availability,
ease of acquisition, and high spatial resolution. However,
pairing PSMA PET with MRI, which has superior soft
tissue resolution than CT, has the potential to provide
additional valuable information for the evaluation of
BCR patients.
Prior studies that investigated the use of PET/MRI in
prostate cancer have focused on patients prior to treat-
ment, given the ability of multiparametric MRI to evalu-
ate primary tumor [9–11]. But combining the molecular,
anatomical, and functional imaging data of PET and
MRI may also allow for precise localization of disease in
patients with BCR. Accordingly, we retrospectively eval-
uated the optimal MRI sequences to localize positive
findings on 68Ga-PSMA-11 PET of patients with BCR
after prostatectomy or radiation therapy.
Methods
This study was approved by the institutional review board,
and written informed consent was obtained from all pa-
tients. This study was performed under an Investigational
New Drug approval from the Food and Drug Administra-
tion as part of a trial prospectively evaluating the accuracy
of 68Ga-PSMA-11 for the detection of prostate cancer
(NCT02611882). Inclusion in the trial required a PSA
doubling time of less than 12 months, and these patients
have been reported as part of a change in management
analysis [12]. Fifty-five consecutive patients who under-
went 68Ga-PSMA-11 PET/MRI for BCR from March 2016
to September 2016 were evaluated. All of the patients
were previously reported in a study evaluating how 68Ga-
PSMA-11 PET changed management in patients with
BCR [12]. This prior study surveyed the referring clini-
cians to determine the effect that the imaging results
would have on patient management but did not compare
the detection rate of different MRI and PET sequences for
suspicious lesions, as was done in this study.
Imaging protocol
Patients were injected with 201.5 ± 52.9 MBq
(5.4 ± 1.4 mCi) of 68Ga-PSMA-11. All but two patients
received furosemide concurrent with the radiotracer in-
jection to prevent scatter artifact from bladder and kid-
ney activity. Images were acquired on a simultaneous
3.0T time-of-flight PET/MRI (Signa, GE Healthcare),
and imaging was performed 65 ± 11 min after injection.
Two PET acquisitions were obtained: the first PET ac-
quisition included two bed positions covering the abdo-
men and pelvis with 8 min of PET acquisition at each
bed position starting with the pelvis bed position. The
second PET acquisition was a whole-body PET acquisi-
tion from the mid-thighs to the vertex obtained for
3 min at each of the six bed positions. The following
MRI sequences were obtained at the two abdominopel-
vic bed positions:
1. Small field of view T2: fast spin echo, flip angle = 125°,
slice thickness = 4.5 mm, number of slices per
acquisition = 27, TE/TR = 129/7567, NEX = 1.5,
field of view (FOV) = 220 × 220 mm, acquisition
matrix 448 × 256
2. Diffusion-weighted images (DWI): axial echo planar
DWI, b values = 50 and 500, slice thickness = 6 mm,
TE/TR = 54/14117, NEX = 1, matrix = 128 × 100
3. Dynamic contrast-enhanced (DCE) imaging with
Differential Subsampling with Cartesian Ordering
(DISCO) [13]: obtained at the pelvis bed position,
slice thickness = 2 mm, flip angle = 15°, matrix
= 512 × 512, TE1/TE2/TR = 2.0/4.1/5.6 msec, NEX
= 0.7, parallel imaging acceleration factors of 2
(phase direction) × 2.5 (slice direction). Following a
single dose (0.1 mmol/kg) of gadobutrol (Gadavist,
Bayer Healthcare, Berlin, Germany), 17 phases were
acquired sequentially with an 11-s temporal resolution.
Three patients did not undergo DCE imaging
4. Post-contrast T1-weighted images (LAVA-FLEX):
axial 3D spoiled gradient echo sequence using two-
point Dixon fat saturation, slice thickness = 3 mm,
flip angle = 12°, matrix size = 316 × 256, TE1/TE2/
TR = 2.0/4.1/5.6, NEX = 0.7.
A whole-body MRI was also obtained at six bed posi-
tions while completing the whole-body PET scan:
1. Axial MR attenuation correction: slice thickness
= 5.2 mm, flip angle = 5°, matrix size = 256 × 128,
TE1/TE2/TR = 1.2/2.3/5.2, NEX = 0.7. The data
were converted to an attenuation map as previously
described [14, 15]
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2. Axial and coronal single-shot fast-spin echo (SSFSE):
TE/TR = 100/576, acquisition matrix 320 × 224,
axial slice thickness = 5 mm, coronal slice thickness
= 6.5 mm. A variable refocusing flip angle was used
as previously described [16]
3. Axial T1 post-contrast images (LAVA-FLEX):
parameters identical to the abdomen and pelvis
acquisition
Image analysis
For each study, up to five PSMA-positive foci were
identified on PSMA PET and grouped into prostate
bed, pelvic lymph nodes, retroperitoneal lymph nodes,
thoracic lymph nodes, cervical lymph nodes, visceral
lesions, and osseous lesions, which were further subca-
tegorized as spine/pelvis, rib, or other osseous lesions.
When more than five PSMA-positive foci were present,
representative lesions were chosen for analysis, with no
more than two lesions in each of the possible categories
when possible. A diagnostic radiologist recorded the
presence or absence of an identifiable correlate for each
radiotracer-avid focus. For disease in the abdomen and
pelvis, the small FOV T2, DWI, and T1-post-contrast
images were analyzed to determine the detection rates
of foci with PSMA uptake. For each lesion, long- and
short-axis measurements were obtained on the se-
quence that best identified it. For lesions above the dia-
phragm, the presence of an identifiable correlate for
each radiotracer-avid focus was evaluated utilizing the
whole-body SSFSE and T1-post-contrast images, and
for each lesion, long- and short-axis measurements
were obtained on the sequence that best identified it.
PET-avid foci were recorded on both the 8-min abdo-
minopelvic acquisition (when applicable) and on the 3-
min whole-body PET acquisition. A board-certified,
fellowship-trained, abdominal radiologist with 4 years
of experience with prostate MRI reviewed all MRI
sequences to detect recurrences in the prostate bed.
Lesions detected in the prostate bed on MRI without
PSMA uptake were considered positive. These were
recorded separately and not included in the calculated
detection rate of MRI for PSMA-positive lesions, given
the absence of PSMA uptake.
Statistical analysis
A chi-square test was used to determine statistical sig-
nificance of differences between proportions of lesions
detected by difference MRI sequences. A level of signifi-
cance of p < 0.05 was used. The 95% confidence inter-
vals were also calculated. The statistical analysis was
conducted using MedCalc for chi-square tests and
www.sample-size.net for confidence intervals.
Results
Table 1 summarizes the demographics, and baseline and
post-treatment clinical characteristics of the study pa-
tient population. Sixteen men underwent primary radical
prostatectomy (16/55, 29.1%), 18, primary radiation ther-
apy—external beam radiation and/or brachytherapy (18/
55, 32.7%), and 21, prostatectomy and radiation therapy
(21/55, 38.2%). The mean PSA at time of PET/MRI was
7.9 ± 12.9 ng/ml, and the mean PSA doubling time was
7.1 ± 6.6 months.
PSMA PET MRI
PSMA-avid foci were detected in 49 patients (49/55,
89.1%): 75.0% (6/8) of patients with a PSA between 0
Table 1 Patient data
Number of patients 55
Age (years)
Mean (SD) 68.3 (6.9)
Range 48–83
Gleason score
3 + 3 9
3 + 4 16
4 + 3 12
4 + 4 6
5 + 3 1
4 + 5 9
5 + 4 1
Unknown 1
PSA at diagnosis (ng/mL)
Mean (SD) 11.2 (12.5)
Range 4.0–88.0
Post-treatment PSA nadir (ng/mL)
Mean (SD) 0.5 (1.1)
Range 0–5.1
Post-treatment PSA (ng/mL)
Mean (SD) 7.9 (12.9)
Range 0.2–84.0
PSA doubling time (months)
Mean (SD) 7.1 (6.6)
Post-treatment PSA grouping (n)
0–1 ng/mL 8 (14.5%)
1–2 ng/mL 10 (18.2%)
> 2 ng/mL 37 (67.3%)
Treatment (n)
Prostatectomy 16 (29.1%)
Radiation 18 (32.7%)
Prostatectomy and radiation 21 (38.2%)
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and 1 ng/mL, 80.0% (8/10), with PSA between 1 and
2 ng/mL, and 94.6% (35/37), with a PSA greater than
2 ng/mL. Nineteen patients (19/55, 34.5%) had positive
PSMA foci suspicious for local recurrence in the pros-
tatic bed. Twenty-nine patients (29/55, 52.7%) had pelvic
or retroperitoneal lymph nodes that were positive on
PSMA PET. Fourteen patients (14/55, 25.5%) had sus-
pected osseous metastases on PSMA PET. No patients
had suspicious visceral uptake. Table 2 details the sites
of suspected recurrent disease on PSMA PET.
Nodal disease
T2-weighted imaging performed the best for localization
of small PSMA-positive lymph nodes (Tables 3 and 4
and Fig. 1a). The higher localization rate of T2-weighted
imaging for lymph nodes less than 1 cm in comparison
to T1 post-contrast and DWI was statistically signifi-
cant (p < 0.001). Example lesions are demonstrated in
Figs. 2 and 3.
Prostate bed lesions
DCE MRI performed better than other MRI sequences
for localization of correlates for suspected prostate bed
recurrence on PSMA PET (Tables 3 and 4 and Fig. 1b).
The difference in sensitivity between DCE and DWI or
single-phase T1 post-contrast was statistically significant
(p = 0.002 and p > 0.001, respectively). The difference in
sensitivity between DCE and T2 was not statistically sig-
nificant (p > 0.05). An example lesion is demonstrated in
Fig. 4. Two additional prostate bed lesions were detected
on DCE MRI without associated PSMA uptake.
Osseous lesions
Small FOV T2 and contrast-enhanced T1-weighted
images were more sensitive for correlates for PSMA-
positive bone foci than SSFSE. Small FOV T2 images
identified correlates for 100% (5/5) of these suspected
bone lesions less than 1 cm and 100% (4/4) suspected
bone lesions greater than 1 cm in the abdomen and pel-
vis. Contrast-enhanced T1 images identified correlates
for 100% (14/14) suspected bone lesions less than 1 cm
and 88.9% (8/9) suspected bone lesions greater than
1 cm in the whole body. SSFSE images identified corre-
lates for 53.8% (7/13) suspected bone lesions less than
1 cm and 62.5% (5/8) suspected bone lesions greater
than 1 cm in the whole body, with two lesions not in-
cluded in the SSFSE field of view.
Lesion detection on long and short PET acquisitions
The 8-min PET acquisition outperformed the 3-min ac-
quisition for the detection of suspected nodal metastases
less than 1 cm (Fig. 5). The 8-min acquisition detected
100% (75/75) of abdominopelvic lymph nodes. The 3-
min acquisition detected 84.0% (63/75) of abdominopel-
vic lymph nodes, including 100% (18/18) lymph nodes
greater than 1 cm and 78.9% (45/57) lymph nodes less
than 1 cm (p < 0.001 for lymph nodes less than 1 cm).
Discussion
In this study, we demonstrated that T2-weighted imaging is
the most effective MRI sequence for identifying anatomic
correlates to 68Ga-PSMA-11 PET-avid abdominopelvic
Table 2 Sites of suspected recurrence on PSMA
Sites of
recurrence
Patients Post RP
(n = 16)
Post RT
(n = 18)
Post RP and
RT (n = 21)
Prostate bed 21 4 15 2
Pelvic lymph
nodes
28 8 8 12
Retroperitoneal
lymph nodes
13 4 3 6
Thoracic lymph
nodes
1 0 1 0
Cervical lymph
nodes
3 0 1 2
Bone (spine/
pelvis)
7 2 0 5
Bone (ribs) 6 0 3 3
Bone (other) 7 1 2 4
Visceral
metastases
0 0 0 0
None 6 4 0 2
RP radical prostatectomy, RT radiation therapy
Table 3 Correlate detection for PSMA-avid foci by sequence in
the abdomen or pelvis
Location Total lesions Small FOV T2 DWI T1 post-contrast DCE
Pelvic lymph nodes
> 1 cm 15 15 14 14
< 1 cm 39 39 19 28
Retroperitoneal lymph nodes
> 1 cm 3 3 3 3
< 1 cm 18 18 10 15
Prostate bed 19 13 7 1 14
aThree patients who had PSMA-positive foci in the prostate bed did not undergo
DCE imaging
Table 4 Detection rates by MRI sequence for abdominopelvic
lymph node correlates to PSMA-positive foci
Sequence Percent detection by sequence (95% CI)
Nodes < 1 cm Nodes > 1 cm Prostate bed
Small FOV T2 100 (93.7–100) 100 (81.5–100) 68.4 (43.4–87.4)
DWI 50.9 (37.3–64.4) 94.4 (72.7–100) 36.8 (16.3–61.6)
T1 post-contrast 75.4 (62.2–85.9) 94.4 (72.7–100) 5.3 (0–26.0)
DCE 87.5 (61.7–98.4)
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lymph nodes, and DCE is most effective for identifying
PSMA-avid foci in the prostatic bed. Also, longer PET
acquisition times increased the detection sensitivity for
subcentimeter PSMA-avid foci.
Early and accurate detection of sites of disease in pa-
tients with BCR allows for patient-specific treatments,
for example, targeted external beam radiation to the
prostate bed or sites of oligometastatic disease, or sys-
temic therapy for more widespread disease [17]. It is im-
portant, therefore, to be able to precisely localize sites of
persistent disease. 68Ga-PSMA-11 PET/MRI may be es-
pecially important in patients with low serum PSA
levels, who may present with subcentimeter nodes. The
high incidence of PSMA-positive lymph nodes less than
1 cm in size indicates that MRI alone would not be as
sensitive for detection of abnormal nodes.
The high sensitivity of PSMA in the study patient
population (89.1%) mirrored that demonstrated in prior
studies [6, 7]. The use of PET/MRI rather than PET/CT
has the potential to detect even more lesions, especially
in the prostate bed, where multiparametric MRI has
been shown to be highly sensitive for detection of sus-
pected local recurrence, including for tumor recurrence
that is not evident on PET [18]. In particular, our results
illustrate the utility of DCE MRI to detect PSMA-avid
foci in the prostatic bed, with a localization rate of
87.5%. DCE MRI has previously been shown to have a
high sensitivity: Haider et al. demonstrated a sensitivity
Fig. 1 Detection rate for abdominopelvic lymph nodes by size and MRI sequence (a). Small FOV T2, DWI, and T1 post-contrast images identify
nearly all PSMA-positive lymph nodes greater than 1 cm. Small FOV T2 is more sensitive than DWI or T1 post-contrast images for lymph nodes
less than 1 cm (p < 0.001). Detection rate for prostate bed recurrence by MRI sequence (b). Dynamic contrast-enhanced imaging (DCE) is more
sensitive than DWI or single-phase T1 post-contrast images for suspected PSMA-avid prostate bed recurrence (p = 0.002 and p < 0.001, respectively).
The difference in sensitivity between DCE and T2 was not statistically significant (p > 0.05)
Fig. 2 A 67-year-old man with biochemical recurrence (PSA of 8.0), who had bilateral pelvic side wall lymph nodes measuring 0.7 and 1.0 cm
seen on T2-weighted imaging (a), PSMA PET (b), post-gadolinium T1-weighted imaging (c), and DWI (d)
Lake et al. EJNMMI Research  (2017) 7:77 Page 5 of 9
of 72% of DCE for recurrence after external beam radio-
therapy, and Rischke et al. demonstrated a sensitivity of
67% of DCE for recurrence after radical prostatectomy
[19, 20], which is also reflected in a meta-analysis by Wu
et al. [21]. The limitations that were observed in sensitiv-
ity of T2-weighted imaging and DWI are likely due to
postoperative and radiation changes in the prostate as
well as artifact from brachytherapy seeds [22–24]. Prior
studies have suggested moderate to high accuracy of
DWI for the detection of recurrent prostate cancer after
radiation therapy [25, 26]. These results suggest that
DCE should be an integral part of a PET/MRI protocol
that aims to detect recurrent tumor in a background of
treatment changes.
Previous work has shown that prostate MRI can be
more sensitive than PSMA PET for suspected local
Fig. 3 A 70-year-old man with biochemical recurrence (PSA of 10.5), who had a left common iliac lymph node measuring 1.3 × 0.6 cm seen on
T2-weighted imaging (a), PSMA PET (b), and post-gadolinium T1-weighted imaging (c). The lymph node was not seen on diffusion-weighted imaging (d)
Fig. 4 A 62-year-old man with biochemical recurrence (PSA of 3.2), who had suspected PSMA-avid prostate bed recurrence measuring 1.0 × 0.6 cm
after initial treatment with brachytherapy, seen on PSMA PET (b) and DCE images (d). The local recurrence was not seen on T2-weighted imaging (a),
post-gadolinium T1-weighted imaging (c), or DWI (not shown due to artifact from brachytherapy seeds)
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recurrence, especially for lesions in close proximity to
the bladder, due to severe scatter artifact associated with
activities in the bladder [18]. This is a potential benefit
of pairing PSMA PET with MRI instead of with CT. In
our study, two additional lesions were detected, which
were identified only on DCE MRI. Scatter did not
appear to limit identification of PSMA-avid lesions on
the PET sequences in our study. It is possible that time-
of-flight reconstructions or furosemide administration
resulted in lower artifact compared to what has been
reported previously using non-time-of-flight PET/MRI
systems [18]. With newer PSMA-targeted imaging
agents that have more prominent biliary excretion, scat-
ter artifact will likely become less of an issue [27, 28].
Although multiparametric MRI (mpMRI) alone or in
conjunction with PSMA PET is highly sensitive for the
detection of prostatic bed recurrence [18–21, 29], dis-
ease is frequently outside the prostatic bed. Thirty of 49
patients with PSMA-positive disease had no evidence of
recurrent cancer in the prostatic bed, but had PSMA up-
take elsewhere. Since sites of suspected recurrence may
be found in many regions outside of prostatic bed, the
combination of mpMRI of the prostate, whole-body
MRI, and PSMA PET is promising for a comprehensive
evaluation of patients with BCR. Although nearly all
PSMA-avid lesions had an MRI correlate, these lesions
would not have been interpreted as metastatic lesions
without PSMA PET. Of note, we did not evaluate osse-
ous lesions that were not PSMA avid, nor was our
protocol optimized to characterize osseous lesions in the
absence of PSMA avidity.
One of the unexpected benefits of simultaneous
PSMA PET/MRI in this study was the added value of
the 8-min PET acquisition compared to the 3-min ac-
quisition for the detection of uptake within small lymph
nodes. This is longer than the recommendation in the
EANM/SNMMI imaging guidelines [30]. The increased
acquisition time was initially implemented to take
advantage of the time used to perform the simultaneous
mpMRI. The 25 cm z-axis length of the detector in
both available simultaneous PET/MRIs allows for doub-
ling the field of view coverage compared to available
PET/CTs, thereby allowing for the doubling of the PET
acquisition time without changing the length of the
study. Though increased uptake time is associated with
increased detection sensitivity [31], the 8-min acquisi-
tion was performed before the 3-min acquisition, so
this likely did not bias the results towards the longer
acquisition. In future implementations, the 8-min ac-
quisition will be combined into the whole-body proto-
col, allowing for a complete whole-body PET/MRI to
be performed in 30 min.
This study has several limitations. First, this is a retro-
spective study, and there is no histopathological correl-
ation of disease for the PSMA-positive foci that were
detected. The majority of patients were treated accord-
ing to the findings of their PET/MRI scans without
biopsy confirmation. It is possible that there were false-
positive PSMA PET-avid foci, although no pathology
proven false-positive lesions are known. The goal of this
study was to identify which MRI sequences should be
used to co-localize suspicious findings, rather than esti-
mating the diagnostic accuracy of PSMA PET/MRI.
Additionally, only a small number of limited MRI
sequences were obtained for localization of PSMA-
positive lesions. It is possible that optimized, dedicated,
MRI sequences would have a better diagnostic perform-
ance; yet, the goal of the study was not to estimate the
diagnostic accuracy of MRI for the detection of PSMA
PET-avid foci, but to identify the best sequences to co-
localize suspicious findings.
Conclusions
A PSMA PET/MRI scan obtained for the assessment
of men with BCR after treatment of prostate cancer
should include small FOV T2 images of the abdomen
Fig. 5 Detection rate for abdominopelvic lymph nodes by size on 3- and 8-min PET acquisitions (a). The 8-min PET is more sensitive for lymph
nodes smaller than 1 cm (p < 0.001). The 3- and 8-min PET detected all lymph nodes larger than 1 cm. Example, 0.7-cm right external iliac lymph
node visible on T2-weighted images (b), fused PET/MR images (c), and on 8-min PET acquisition (d), but not seen on 3-min PET acquisition (e).
The right ureter is designated with a black arrow
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and pelvis and DCE MRI of the pelvis to improve co-
localization of suspicious findings identified on PSMA
PET. In addition, a longer 8-min PET acquisition may
improve the detection of small foci of a suspected
recurrent cancer.
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